Qiagen N V (QGEN) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Qiagen N v   (NYSE: QGEN)

Select the Financial Report: Select the Period:


Description of Qiagen N V's Business Segments


Qiagen N.V. is a prominent global biotech company that focuses on providing specialized sample and assay technologies for various sectors within the life sciences. Its offerings are crucial in molecular diagnostics, applied testing, academic and pharmaceutical research, genomic analysis, and personalized healthcare. The company operates across several segments, each catering to distinct applications and audiences.

Segments

1. Life Sciences:
This segment encompasses a wide array of products and solutions tailored for genomic research. Key offerings include:
- Gene Expression Analysis: Tools and reagents for measuring gene expression levels in various biological samples.
- Next-Generation Sequencing (NGS): Comprehensive workflows and reagents for NGS, facilitating large-scale genomic studies with high accuracy.
- Mutation Detection: Technologies designed to identify genetic mutations and variations, which are pivotal in cancer research and genetic disorders.
- High-Throughput PCR and qPCR Systems: Automated platforms for performing quantitative PCR, enabling researchers to conduct multiple assays simultaneously.
- Bioinformatics Software: Solutions for managing and analyzing large datasets generated from genomic research, including tools for variant interpretation and molecular data analysis.
- Sample Preparation Kits: Dedicated kits for the extraction and purification of DNA and RNA from various sample types.

2. Molecular Diagnostics:
This segment is essential for healthcare and clinical settings, focusing on the rapid and precise detection of diseases:
- Infectious Disease Detection: Assays and testing kits designed to identify viral, bacterial, and parasitic infections quickly, contributing to timely diagnosis and treatment.
- Oncology Testing: A variety of solutions that enable the detection of cancer-related biomarkers, supporting personalized treatment plans.
- Genetic Disorder Testing: Tools for detecting hereditary conditions, ensuring early diagnosis and intervention strategies.
- Automated Laboratory Systems: Integrated solutions for clinical labs, aimed at streamlining workflows and improving accuracy in diagnostic testing.

3. Applied Testing:
This segment focuses on testing solutions tailored for environmental safety, food industry, forensic analysis, and veterinary diagnostics:
- Environmental Monitoring: Tools and assays for detecting contaminants in air, soil, and water, addressing public health and safety concerns.
- Food and Water Safety Testing: Products ensuring the microbiological safety of consumables, essential for regulatory compliance in the food and beverage sector.
- Forensics: Technologies used in criminal investigations, including DNA profiling and analysis.
- Plant and Animal Genotyping: Solutions aiding in agricultural research and veterinary diagnostics, crucial for breeding programs and disease management.

Products and Services

Qiagen N.V. boasts an extensive portfolio that addresses various needs across the life science sector:

1. Sample and Assay Technologies:
Qiagen provides a comprehensive range of kits and reagents enabling the isolation, purification, and analysis of biomolecules (DNA, RNA, proteins) pivotal in various research and diagnostic applications.

2. Automated Instruments:
To enhance efficiency in sample processing, Qiagen offers advanced automation solutions, including:
- Liquid Handling Systems: Automating steps in sample preparation and assay workflows.
- Nucleic Acid Extraction Platforms: Devices designed to streamline extraction processes, significantly reducing manual handling.

3. Molecular Diagnostics Solutions:
Qiagen presents a robust suite of molecular diagnostic products, which include:
- Real-time PCR Assays: High-fidelity tests for detecting specific nucleic acids in biological samples.
- Hybridization Assays: Techniques designed for the detection of specific DNA or RNA sequences.
- Automation Systems: Integrated solutions that enhance laboratory efficiencies and reduce error rates in clinical testing environments.

4. Bioinformatics Software:
Qiagen develops software that aids in the analysis of genomic data, offering tools for:
- DNA and RNA Sequencing Analysis: Facilitating the interpretation of results from sequencing experiments.
- Pathway Analysis and Biological Network Software: Supporting researchers in understanding the biological implications of their findings.

5. Research Services:
Qiagen provides extensive research services aimed at:
- Genomic Analysis: Assisting clients in undertaking complex genomic studies.
- Biomarker Discovery: Supporting the identification of new biomarkers for diseases.
- Assay Development: Collaborating with pharmaceutical and biotech companies to develop and optimize diagnostic assays.

Conclusion

Qiagen N.V. is at the forefront of biotechnological advancements, empowering researchers, clinicians, and businesses across the life sciences spectrum. Its innovative products and services are instrumental in expediting scientific progress, enhancing personalized healthcare solutions, and ultimately improving patient outcomes and quality of life. The company’s broad range of offerings ensures that it meets the diverse and evolving needs of its various customer segments in the life sciences industry.




Annual Report on Qiagen N v Divisions, Sales by Country

 
Consumables and related revenues   Consumables and related revenues Segment contribution to total sales 92.23 % of total Revenue
Instruments   Instruments Segment contribution to total sales 10.5 % of total Revenue
Sample technologies   Sample technologies Segment contribution to total sales 32.5 % of total Revenue
Diagnostic solutions   Diagnostic solutions Segment contribution to total sales 39.47 % of total Revenue
PCR Nucleic acid amplification   PCR Nucleic acid amplification Segment contribution to total sales 15.19 % of total Revenue
Genomics NGS   Genomics NGS Segment contribution to total sales 11.88 % of total Revenue
Other   Other Segment contribution to total sales 3.68 % of total Revenue
Reportable Segment   Reportable Segment Segment contribution to total sales 102.73 % of total Revenue
Netherlands   Netherlands Segment contribution to total sales 1.16 % of total Revenue
Total Americas   Total Americas Segment contribution to total sales 53.4 % of total Revenue
United States   United States Segment contribution to total sales 49.08 % of total Revenue
Other Americas   Other Americas Segment contribution to total sales 4.33 % of total Revenue
Europe Middle East and Africa   Europe Middle East and Africa Segment contribution to total sales 35.03 % of total Revenue
Asia Pacific Japan and Rest of World   Asia Pacific Japan and Rest of World Segment contribution to total sales 14.29 % of total Revenue


Twelve months ended 2025
QGEN s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
Consumables and related revenues 1,876.42 92.23 %
Instruments 213.58 10.5 %
Sample technologies 661.27 32.5 %
Diagnostic solutions 803.08 39.47 %
PCR Nucleic acid amplification 308.99 15.19 %
Genomics NGS 241.78 11.88 %
Other 74.89 3.68 %
Reportable Segment 2,090.00 102.73 %
Netherlands 23.70 1.16 %
Total Americas 1,086.51 53.4 %
United States 998.45 49.08 %
Other Americas 88.07 4.33 %
Europe Middle East and Africa 712.76 35.03 %
Asia Pacific Japan and Rest of World 290.73 14.29 %
Total 2,034.50 100 %


Twelve months ended 2025
QGEN s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Reportable Segment 1,299.50 62.18 %
Total 424.88 20.88 %

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
Consumables and related revenues 6.6 % -
Instruments -2.02 % -
Sample technologies 3 % -
Diagnostic solutions 7.24 % -
PCR Nucleic acid amplification 2.84 % -
Genomics NGS 3.5 % -
Other 40.71 % -
Reportable Segment 5.65 % 34.34 %
Netherlands 13.4 % -
Total Americas 5.33 % -
United States 5.99 % -
Other Americas -1.67 % -
Europe Middle East and Africa 9.91 % -
Asia Pacific Japan and Rest of World -2.49 % -
Molecular Diagnostics - -
Life Sciences - -
Consumables and related Molecular Diagnostics - -
Consumables and related Life Sciences - -
Instruments Molecular Diagnostics - -
Instruments Life Sciences - -
Total 6 % 408.28 %



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.